Sotatercept shows promise for a type of pulmonary hypertension linked to heart failure with preserved EF

Sotatercept significantly improved pulmonary vascular resistance and exercise capacity in patients with PH-HFpEF. The promising results were presented at ACC.26 and published in Circulation.